Combination Therapy for First Line Treatment of Advanced Cervical Cancer
This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient with metastatic 、persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both (Stage IA-IVA).
Advanced Cervical Cancer
DRUG: Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin
Safety: adverse events as assessed by CTCAE v5.0, 36 months
Progression free survival, 36 months|Overall survival, 36 months|Objective response rate, 36 months|Disease control rate, 36 months|Duration of response, 36 months
Advanced cervical cancer patients with metastatic, persistent or recurrent disease after radical surgery、radical platinum-based concurrent chemoradiotherapy or both will be treated by Paclitaxel plus Cisplatin\\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib.